Characteristics of new users of low-dose aspirin and non-users matched by age, gender and region of residence, Denmark, 2005–2013
| Characteristic | New users | Non-users |
| (n=412 202) | (n=1 236 560) | |
| Median age at index date (IQR*) | 66.2 (57.7–75.5) | 66.2 (57.7–75.5) |
| Sex | ||
| Female | 195 900 (47.5) | 587 688 (47.5) |
| Male | 216 302 (52.5) | 648 872 (52.5) |
| Age | ||
| 0–49 years | 46 197 (11.2) | 138 920 (11.2) |
| 50–69 years | 205 601 (49.9) | 616 865 (49.9) |
| 70+ years | 160 404 (38.9) | 480 775 (38.9) |
| Calendar period | ||
| 2005–2007 | 175 482 (42.6) | 526 430 (42.6) |
| 2008–2010 | 144 071 (34.9) | 432 195 (34.9) |
| 2011–2013 | 92 649 (22.5) | 277 935 (22.5) |
| Charlson Comorbidity Index score† | ||
| None (0) | 203 891 (49.5) | 913 082 (73.8) |
| Medium (1–2) | 164 290 (39.9) | 264 557 (21.4) |
| High (3+) | 44 021 (10.7) | 58 921 (4.8) |
| Alcoholism-related disorders | 13 731 (3.3) | 25 187 (2.0) |
| Chronic liver disease | ||
| Mild | 4648 (1.1) | 8877 (0.7) |
| Moderate to severe | 1141 (0.3) | 2758 (0.2) |
| Chronic obstructive pulmonary diseases | 22 403 (5.4) | 38 854 (3.1) |
| Haemorrhoids | 17 441 (4.2) | 44 612 (3.6) |
| Diverticular disease | 13 324 (3.2) | 30 651 (2.5) |
| Diabetes mellitus | 32 453 (7.9) | 34 796 (2.8) |
| Obesity | 16 222 (3.9) | 23 175 (1.9) |
| Concomitant drugs‡ | ||
| Non-aspirin NSAIDs | 120 438 (29.2) | 279 208 (22.6) |
| High-dose aspirin | 72 (0.0) | 106 (0.01) |
| Hormone replacement therapy | 33 237 (8.1) | 90 033 (7.3) |
| Statins | 191 455 (46.4) | 142 884 (11.5) |
| Corticosteroids | 32 517 (7.9) | 65 344 (5.3) |
| Insulin and analogues | 15 252 (3.7) | 14 713 (1.2) |
| Oral antidiabetic drugs | 43 537 (10.6) | 45 777 (3.7) |
| Antithrombotic treatment§ | 68 521 (16.6) | 52 101 (4.2) |
| Vitamin K-antagonists | 25 037 (6.1) | 41 963 (3.4) |
| Heparins | 1195 (0.3) | 902 (0.1) |
| Thienopyridines | 38 758 (9.4) | 9043 (0.7) |
| Thrombine inhibitors | 926 (0.2) | 1124 (0.1) |
| Factor X inhibitors | 100 (0.0) | 121 (0.0) |
| Nucleotide/nucleoside analogues | 5170 (1.2) | 33 (0.0) |
| Calcium channel blockers | 90 133 (21.9) | 137 077 (11.1) |
| ACE inhibitors | 115 160 (27.9) | 144 009 (11.6) |
*IQR.
†Excluding colorectal cancer from the index (date of first-time prescription for low-dose aspirin).
‡Prescription redemption within 1 year prior to the index date.
§Vitamin-K-antagonists (warfarin, phenprocoumon), heparins (dalteparin, tinzaparin, enoxaparin, heparin), thienopyridines (dipyridamole, clopidogrel, prasugrel), factor X inhibitors (rivaroxaban, apixaban, fondaparinux), nucleotide/nucleoside analogues (ticagrelor, congrelor).
NSAID, non-steroidal anti-inflammatory drug.